Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials

Ariadna Contreras, Aaron F. Orozco, Micheline Resende, Robert C. Schutt, Jay H. Traverse, Timothy D. Henry, Dejian Lai, John P. Cooke, Roberto Bolli, Michelle L. Cohen, Lem Moyé, Carl J. Pepine, Phillip C. Yang, Emerson C. Perin, James T. Willerson, Doris A. Taylor, the Cardiovascular Cell Therapy Research Network (CCTRN) For the Cardiovascular Cell Therapy Research Network (CCTRN)

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Autologous bone marrow mononuclear cell (BM-MNC) therapy for patients with ST-segment elevation myocardial infarction (STEMI) has produced inconsistent results, possibly due to BM-MNC product heterogeneity. Patient-specific cardiovascular risk factors (CRFs) may contribute to variations in BM-MNC composition. We sought to identify associations between BM-MNC subset frequencies and specific CRFs in STEMI patients. Bone marrow was collected from 191 STEMI patients enrolled in the CCTRN TIME and LateTIME trials. Relationships between BM-MNC subsets and CRFs were determined with multivariate analyses. An assessment of CRFs showed that hyperlipidemia and hypertension were associated with a higher frequency of CD11b+ cells (P = 0.045 and P = 0.016, respectively). In addition, we found that females had lower frequencies of CD11b+ (P = 0.018) and CD45+CD14+ (P = 0.028) cells than males, age was inversely associated with the frequency of CD45+CD31+ cells (P = 0.001), smoking was associated with a decreased frequency of CD45+CD31+ cells (P = 0.013), glucose level was positively associated with the frequency of CD45+CD3+ cells, and creatinine level (an indicator of renal function) was inversely associated with the frequency of CD45+CD3+ cells (P = 0.015). In conclusion, the frequencies of monocytic, lymphocytic, and angiogenic BM-MNCs varied in relation to patients’ CRFs. These phenotypic variations may affect cell therapy outcomes and might be an important consideration when selecting patients for and reviewing results from autologous cell therapy trials.

Original languageEnglish (US)
Article number3
JournalBasic research in cardiology
Volume112
Issue number1
DOIs
StatePublished - Jan 1 2017

Bibliographical note

Funding Information:
This work was supported by the National Heart, Lung, and Blood Institute under cooperative agreement 5 UM1 HL087318. It was also supported, in part, by National Heart, Lung, and Blood Institute contracts N01 HB 37164 and HHSN268201000008C, which were awarded to the Molecular and Cellular Therapeutics Facility, University of Minnesota, and by contracts N01 HB 37163 and HHSN268201000007C, which were awarded to the Cell Processing Facility, Baylor College of Medicine. Further funding provided by National Center for Research Resources CTSA Grant UL1 TR000064 awarded to the University of Florida. In addition, funding from the Texas State Legislature was used to assist investigators at the Texas Heart Institute, Houston, Texas.

Publisher Copyright:
© 2016, Springer-Verlag Berlin Heidelberg.

Keywords

  • Autologous cell therapy
  • Bone marrow mononuclear cells
  • Cardiovascular risk factors
  • Ischemic heart disease
  • ST-segment elevation myocardial infarction

Fingerprint

Dive into the research topics of 'Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials'. Together they form a unique fingerprint.

Cite this